Ro 63-0563

Ro 63-0563
[[File:|frameless|220px|alt=|Chemical structure of Ro 63-0563]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Investigational
CAS Number	123456-78-9
PubChem	123456
DrugBank
ChemSpider	123456
KEGG

Ro 63-0563 is a chemical compound that has been studied for its potential use as a pharmaceutical drug. It is primarily known for its role as a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor family. This receptor is predominantly found in the central nervous system and is implicated in various neurological processes, including cognition and mood regulation.

Pharmacology

Ro 63-0563 acts as a selective antagonist at the 5-HT6 receptor. By blocking this receptor, Ro 63-0563 can modulate the release of various neurotransmitters such as acetylcholine, dopamine, and glutamate, which are involved in cognitive processes. This has led to interest in Ro 63-0563 as a potential treatment for cognitive disorders such as Alzheimer's disease and schizophrenia.

Mechanism of Action

The 5-HT6 receptor is a G-protein coupled receptor (GPCR) that is positively coupled to adenylate cyclase. Antagonism of this receptor by Ro 63-0563 results in decreased cyclic AMP (cAMP) levels, which in turn affects downstream signaling pathways involved in neurotransmitter release and synaptic plasticity.

Research and Development

Ro 63-0563 has been the subject of various preclinical studies. Animal models have shown that Ro 63-0563 can improve performance in tasks that require learning and memory, suggesting its potential utility in treating cognitive impairments. However, as of the latest updates, Ro 63-0563 remains an investigational compound and has not been approved for clinical use.

Potential Applications

Due to its effects on cognitive function, Ro 63-0563 is being explored for its potential in treating:

• Alzheimer's disease
• Schizophrenia
• Attention deficit hyperactivity disorder (ADHD)

Safety and Efficacy

The safety profile of Ro 63-0563 is still under investigation. Preclinical studies have not reported significant adverse effects, but comprehensive clinical trials are necessary to establish its safety and efficacy in humans.

Also see

• 5-HT6 receptor
• Serotonin receptor
• Cognitive enhancer
• Neurotransmitter